● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.38 for the 2019 fiscal year.
● Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
● The stock is currently in contact with a medium-term resistance that must be gotten rid of so as to resume the upward trend.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 53.97 times its estimated earnings per share for the ongoing year.
● For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
● Analysts covering the stock have recently lowered their earnings forecast.
● For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
● For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
● The underlying tendency is negative on the weekly chart below the resistance at 31.66 EUR